Table 1.
The demographic and clinical characteristics of the patients (n = 147) at the time of DECT
| Age, mean (SD), (years) | 63.3 (13.6) |
| Sex, (N, %) | |
| Male | 100 (68) |
| Female | 47 (32) |
| Body mass index, mean (SD), (kg/m2) | 28.5 (4.9) |
| Cardiovascular disease (N, %) | 57 (39) |
| Diabetes mellitus (N, %) | 21 (14.4) |
| Disease duration median (IQR), (years) | 3 (6.6) |
| Frequency of attack during the past year (N, %) | |
| 0–2 | 51 (34.5) |
| ≥ 3 | 80 (54.1) |
| Unknown | 17 (11.5) |
| Uric acid levels between flares, mean (SD), (μmol/l) | 442.5 (124.0) |
| Joint involvement at the moment of DECT (N, %) | |
| MTP1 | 52 (62.8) |
| Other joints | 93 (35.1) |
| Unknown | 3 (2.0) |
| Result microscopy of the index joint | |
| Diagnostic joint aspiration of the index joint (N, %) | 86 (58.5) |
| MSU crystals present (N, %) | 25 (17.0) |
| MSU crystals absent (N, %) | 61 (41.5) |
| Clinical evidence of tophi N, (%) | 26 (17.8) |
| Urate lowering therapy (allopurinol, benzbromarone, and febuxostat use at the moment of DECT) (N, %) | |
| Yes | 28 (19.3) |
| No | 115 (80.0) |
| Unknown | 4 (0.7) |